FTC and NY sue Daraprim maker over access to samples
The Federal Trade Commission and state of New York have alleged that Vyera Pharmaceuticals broke federal antitrust laws by denying access to samples that competitors needed to replicate its infection-treating drug.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10